PT  - JOURNAL ARTICLE
AU  - F Backes
AU  - J Fowler
AU  - L Copeland
AU  - L Wei
AU  - D O’Malley
AU  - D Cohn
AU  - C Cosgrove
AU  - J Hays
AU  - K Bixel
TI  - OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer
AID  - 10.1136/ijgc-2021-IGCS.24
DP  - 2021 Nov 01
TA  - International Journal of Gynecologic Cancer
PG  - A13--A14
VI  - 31
IP  - Suppl 4
4099  - http://ijgc.bmj.com/content/31/Suppl_4/A13.3.short
4100  - http://ijgc.bmj.com/content/31/Suppl_4/A13.3.full
SO  - Int J Gynecol Cancer2021 Nov 01; 31
AB  - Objectives To estimate the maximally tolerated dose (MTD) and toxicities associated with MIRV and rucaparib.Methods Patients had to be folate receptor α (FRα) positive by IHC (≥25% of tumor staining at ≥2+ intensity). Using a 3+3 design patients received MIRV (4–6 mg/kg IV every 3 weeks) and rucaparib PO BID (400–600 mg) depending on the dose level.Results >100 patients were screened for FRα expression; 21 have been enrolle, 16 with ovarian and 5 with endometrial cancer. Median age was 64.5, with 3 (range 1–9) prior lines of treatment. 6 patients completed DL2 (5/500), however, 2 DLTs (grade 3 fatigue), let us to establish the RP2D at DL1 (MIRV 5 mg/kg IV every 3 weeks and rucaparib 400 mg PO BID). Treatment related toxicities (all grades) occurring in ≥25% of patients included fatigue (73%), nausea (67%), blurred vision (60%), anemia (47%), anorexia (47%), mucositis (40%), ALT/AST elevated (40%), dry eyes (33%), vomiting (27%), thrombocytopenia (27%), weight loss (27%), leukopenia (27%), dysgeusia (27%). Grade ≥3 toxicities were fatigue (20%), pneumonitis (13%), anemia (13%), diarrhea (7%), cataract (7%), lymphopenia (7%), thrombocytopenia (7%), weight loss (7%), hypokalemia (7%). Sixteen patients are currently evaluable for response; 6 (37.5%) with PR, 8 (50%) SD, 2 (12.5%) PD; ORR 33% (4/12) in ovarian cancer and 50% (2/4) in endometrial cancer. Median PFS is 6.3 months with 95%CI (0.7, 13.8) months.Conclusions Combination rucaparib and MIRV was tolerable with mostly manageable side effects and encouraging activity in this heavily pretreated population (including prior PARPi) of both endometrial and ovarian cancer.